Unknown

Dataset Information

Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors.


ABSTRACT: Several groups have proposed that genotypic determinants in gag and the gp41 cytoplasmic domain (gp41-CD) reduce protease inhibitor (PI) susceptibility without PI-resistance mutations in protease. However, no gag and gp41-CD mutations definitively responsible for reduced PI susceptibility have been identified in individuals with virological failure (VF) while receiving a boosted PI (PI/r)-containing regimen. To identify gag and gp41 mutations under selective PI pressure, we sequenced gag and/or gp41 in 61 individuals with VF on a PI/r (n = 40) or NNRTI (n = 20) containing regimen. We quantified nonsynonymous and synonymous changes in both genes and identified sites exhibiting signal for directional or diversifying selection. We also used published gag and gp41 polymorphism data to highligh

SUBMITTER: Manasa J 

PROVIDER: S-EPMC5599673 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature